General Indian drug controller (DCGI) on Friday gave the Indian Serum Institute to produce Covid-19 Vaksin Russia Sputnik V in India.
The Indian Serum Institute (SII) has been given approval to produce vaccines for examination, tests and analysis with certain conditions at licensed facilities in Hadapsar, Pune. SII has submitted an application to DCGI in this case on Wednesday.
Pune-based companies have collaborated with the Gamaleya Research Institute of Epidemiology and Microbiology, Moscow in Russia to develop Sputnik V in India.
SII has produced the Oxford AstraZeneca Covid-19 vaccine with the name ‘Covishield’ and has told the government to supply 10 crore doses in June. Serum Institute also produces Novavax vaccines, the regulatory permit awaited from the US.
Sputnik V in India
Russia Sputnik V was authorized for emergency use (EUA) by DCGI in April. After Hetero Biofarma, Gland Pharma, Panacea Biotec, Stasis Biopharma and Virchow Biotech, SII is the sixth pharmaceutical company that will produce Sputnik V in India.
Import doses are priced at RS 995.40 per dose and Dr. Reddy has indicated that prices will be lower after local inventories begin.
The first LOT Sputnik vaccine made in India accepted permission on Tuesday from the Central Medicine Laboratory, Kasauli.